Targeting tumor-associated macrophages using mRNA lipid nanoparticles for cytotoxic T lymphocyte–mediated cancer immunotherapy
Science Advances · 2026
DOI: 10.1126/sciadv.aed9568 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, 2026. Verfasst von Rui Chen und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Chemical Engineering, College of Engineering and IT, Adelaide University, Adelaide, SA, Australia. Hauptthemen laut MEDLINE: T-Lymphocytes, Cytotoxic, Nanoparticles, Immunotherapy, Tumor-Associated Macrophages. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Health and Medical Research Council projects of Australia.
Abstract (Originalsprache)
The immunosuppressive tumor microenvironment (TME) remains one of the main obstacles that limit responsiveness to immunotherapy. Recently, lipid nanoparticles carrying messenger RNA (mRNA) have emerged as a promising strategy to modulate the immunosuppressive TME, with the ultimate goal of sustaining anticancer immunity of cytotoxic T lymphocytes (CTLs). However, there are challenges with mRNA-based cytokine/chemokine therapies such as the lack of specific targeting, low therapeutic efficacy, and elevated toxicity, raising concerns about their clinical translation. Here, we have developed an antibody-coated lipid nanoparticle (Ab-LNP) delivery system that targets the protein triggering receptor expressed on myeloid cells 2 (TREM2) expressed by tumor-associated macrophages (TAMs). We demonstrate that codelivery of a Toll-like receptor agonist and CXCL9-encoding mRNA encapsulated in our Ab-LNP successfully ameliorates immunosuppression and improves tumor infiltration and activity of CTLs. Further combination with immune checkpoint inhibitors against PD-L1 and CTLA-4 promoted a CTL-favoring immunological environment and durable memory immunity. Our Ab-LNPs targeting TAMs highlight the potential of reprogramming immunosuppressive TME to enhance CTL activity for improved response to cancer immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Chemical Engineering, College of Engineering and IT, Adelaide University, Adelaide, SA, Australia.
- Translational Oncology Laboratory, Centre for Cancer Biology, SA Pathology and Adelaide University, Adelaide, SA, Australia.
- School of Medicine, Adelaide University, Adelaide, SA, Australia.
- Faculty of Health and Medical Sciences, School of Biomedicine, Adelaide University, Adelaide, SA, Australia.
- Viral Immunology Group, Discipline of Surgery, Basil Hetzel Institute for Translational Medicine, Adelaide University, SA, Australia.
- Cancer Clinical Trials Unit, Royal Adelaide Hospital, Adelaide, SA, Australia.
ORCID-Profile: Rui Chen, Letao Xu, Ruoxuan Jia, Dawn M Whelan, Michael P Brown, Chun-Xia Zhao
Förderung
- National Health and Medical Research Council projects of Australia
Zitieren
APA
Chen, R., Xu, L., Staudacher, A. H., Wang, X., Jia, R., Finnie, J. W., Wang, X., Whelan, D. M., Brown, M. P., & Zhao, C. X. (2026). Targeting tumor-associated macrophages using mRNA lipid nanoparticles for cytotoxic T lymphocyte–mediated cancer immunotherapy. Science Advances. https://doi.org/10.1126/sciadv.aed9568
Vancouver
Chen R, Xu L, Staudacher AH, Wang X, Jia R, Finnie JW, et al. Targeting tumor-associated macrophages using mRNA lipid nanoparticles for cytotoxic T lymphocyte–mediated cancer immunotherapy. Science Advances. 2026. doi:10.1126/sciadv.aed9568
BibTeX
@article{Chen2026,
author = {Chen, Rui and Xu, Letao and Staudacher, Alexander H and Wang, Xing and Jia, Ruoxuan and Finnie, John W and Wang, Xiaoyan and Whelan, Dawn M and Brown, Michael P and Zhao, Chun-Xia},
title = {Targeting tumor-associated macrophages using mRNA lipid nanoparticles for cytotoxic T lymphocyte–mediated cancer immunotherapy},
journal = {Science Advances},
year = {2026},
doi = {10.1126/sciadv.aed9568}
}
EUVIMED